Alzheimer's Disease Treatment: Current Evidence and Emerging Therapies — Cost, Top Hospitals & Success Rates | MyMedicPlus

Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60–80% of all dementia diagnoses and affecting an estimated 55 million people worldwide — a figure projected to triple by 2050 as populations age. It is a progressive, irreversible neurodegenerative disorder characterised at the molecular level by two cardinal pathological hallmarks: extracellular amyloid-beta (A-beta) plaques and intraneuronal neurofibrillary tau tangles, which together drive neuronal loss, synaptic dysfunction, and the clinical syndrome of progressive cognitive and functional decline.

The AT(N) biomarker framework, proposed by the National Institute on Aging-Alzheimer's Association (NIA-AA) in 2018, classifies AD pathophysiology into three domains: A (amyloid-beta deposition, measured by PET or CSF A-beta42/40 ratio), T (tau pathology, measured by tau PET or CSF phospho-tau, particularly p-tau217), and N (neurodegeneration/neuronal injury, measured by hippocampal atrophy on MRI, FDG-PET hypometabolism, or CSF total tau). Individuals with A+ T+ N+ carry confirmed Alzheimer's biology and are most likely to benefit from disease-modifying therapies targeting amyloid.

Blood-based biomarkers — particularly plasma p-tau217 — have emerged as highly accurate, minimally invasive screening tools for AD pathology (AUC 0.90–0.96 versus amyloid PET gold standard), enabling far broader access to early diagnosis without requiring lumbar puncture or expensive PET imaging. This has fundamentally transformed the diagnostic pathway in memory clinics internationally.

The clinical disease spectrum spans: preclinical AD (biomarker-positive, cognitively normal), mild cognitive impairment (MCI) due to AD, and Alzheimer's dementia in mild, moderate, and severe stages. The major genetic risk factor is APOE4 allele carriage, which increases lifetime AD risk by 3–4 fold (one copy) to 8–12 fold (two copies) compared to APOE3 homozygotes.

Alzheimer's disease treatments target different stages and subtypes of the condition, with therapy selection guided by clinical stage, biomarker status, and genetic risk profile:

• Mild-to-moderate Alzheimer's dementia: The primary indication for cholinesterase inhibitors (ChEI). Characterised by episodic memory loss, word-finding difficulty, visuospatial impairment, and executive dysfunction, with preserved basic activities of daily living early in the course.
• Moderate-to-severe Alzheimer's dementia: Indication for memantine, often added to ongoing ChEI therapy. Characterised by significant ADL dependence, behavioural and psychological symptoms of dementia (BPSD) including agitation, delusions, and sleep disturbance, and communication impairment.
• Early Alzheimer's disease (MCI or mild dementia with confirmed amyloid pathology): The target population for FDA-approved anti-amyloid monoclonal antibodies — lecanemab and donanemab. Eligibility requires: (a) clinical confirmation of MCI or mild AD dementia; (b) confirmed amyloid pathology by amyloid PET or CSF A-beta42/40 ratio; (c) MMSE typically 22–30; (d) CDR Global score 0.5–1.
• Familial/early-onset Alzheimer's disease: Caused by autosomal dominant mutations in PSEN1 (Presenilin 1), PSEN2 (Presenilin 2), or APP (amyloid precursor protein). Onset typically before age 65, sometimes as early as 30s–40s. Currently managed with ChEIs and memantine; clinical trials specifically targeting dominantly inherited AD are ongoing (DIAN-TU platform).
• BPSD (Behavioural and Psychological Symptoms of Dementia): Agitation, aggression, sleep disorders, depression, anxiety, and psychosis affect up to 90% of people with AD at some point. Require dedicated non-pharmacological-first management approaches and pharmacological intervention (low-dose atypical antipsychotics, SSRIs, melatonin) only when necessary.
• Modifiable risk prevention: The Lancet Commission 2024 identified 14 modifiable risk factors — including midlife hypertension, hearing loss, depression, physical inactivity, social isolation, traumatic brain injury, air pollution, high LDL cholesterol (newly added in 2024), and untreated visual loss — collectively accounting for approximately 45% of dementia cases that could theoretically be prevented or delayed.

Eligibility criteria differ substantially by treatment modality:

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): Indicated for mild-to-moderate AD dementia (MMSE 10–26). Donepezil is also licensed for severe AD in many countries. No specific biomarker confirmation is required for ChEI prescription — clinical diagnosis by a specialist in memory disorders is sufficient. Relative contraindications include sick sinus syndrome, severe asthma or COPD (rivastigmine patch preferred over oral formulation), and active peptic ulcer disease.

Memantine: Indicated for moderate-to-severe AD (MMSE below 20) or as add-on to ChEI in moderate-stage disease. Caution in severe renal impairment (dose reduction required at GFR below 30 mL/min). Generally well tolerated in the elderly.

Lecanemab (Leqembi, Eisai/Biogen) and donanemab (Kisunla, Eli Lilly): Both require:

• Clinical diagnosis of MCI or mild Alzheimer's dementia by a specialist (neurologist, geriatrician, or psychiatrist with memory expertise).
• Confirmed amyloid pathology: Either amyloid PET scan (18F-florbetapir, 18F-florbetaben, or 18F-flutemetamol) showing moderate-to-high amyloid burden, OR CSF A-beta42/40 ratio below the validated threshold, OR plasma p-tau217 above validated threshold (increasingly used for initial screening).
• MMSE 22–30 (mild cognitive impairment range) or CDR 0.5–1 (very mild to mild dementia).
• Brain MRI within 12 months excluding alternative diagnoses and assessing pre-treatment microhemorrhage burden (more than 4 microhemorrhages on FLAIR/SWI is a contraindication).
• APOE4 status: Both agents require APOE genotyping before initiation due to significantly elevated ARIA risk in APOE4 homozygotes (up to 33% ARIA-E rate in e4/e4 patients on lecanemab). Prescribers must discuss individualised benefit-risk in APOE4 carriers, particularly homozygotes.
• Exclusion of contraindicated medications: anticoagulants increase haemorrhagic ARIA risk; use with caution or contraindicated depending on protocol.

Symptomatic pharmacological therapies:

• Donepezil (Aricept): Most widely prescribed ChEI globally. Dose: 5 mg daily for 4 weeks then 10 mg daily (10 mg nightly preferred to reduce GI side effects). Extended to 23 mg daily in the US for severe AD. Reversible, selective acetylcholinesterase inhibitor; once daily dosing improves adherence.
• Rivastigmine (Exelon): Dual inhibitor of acetylcholinesterase and butyrylcholinesterase. Available as transdermal patch (4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h) — patch formulation significantly reduces GI side effects compared to capsules. Preferred in patients with Parkinson's disease dementia or Lewy body dementia.
• Galantamine (Reminyl ER): Acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator. Dose: 8 mg ER daily for 4 weeks, 16 mg ER daily for 4 weeks, then 24 mg ER daily. Extended-release once-daily formulation available.
• Memantine (Ebixa/Namenda): NMDA receptor antagonist that reduces glutamate-mediated excitotoxicity. Dose: 5 mg weekly titration to 20 mg daily (10 mg twice daily or 28 mg XR once daily). Evidence for benefit in moderate-to-severe AD; modest evidence for combination with ChEI (Namzaric fixed-dose combination in US).

Disease-modifying anti-amyloid therapies (DMTs):

• Lecanemab (Leqembi): Anti-amyloid protofibrils IgG1 monoclonal antibody. CLARITY AD Phase 3 trial (N=1,795, 18 months, NEJM 2022): 27% slowing of clinical decline on CDR-SB primary endpoint versus placebo (p<0.001); significant amyloid clearance on PET from week 13. Dose: 10 mg/kg IV every 2 weeks. ARIA-E 21.5%, ARIA-H 17%; symptomatic ARIA 3%.
• Donanemab (Kisunla): Anti-N3pG amyloid IgG1 antibody targeting pyroglutamate amyloid. TRAILBLAZER-ALZ2 trial (N=1,736, 18 months, JAMA 2023): 35% slowing of decline in low-medium tau subgroup (primary pre-specified endpoint). Complete amyloid clearance achieved in 71% of participants at 12 months, after which dosing was discontinued — a unique 'stop when clear' protocol. Dose: 700 mg IV monthly for 3 doses then 1400 mg IV monthly until amyloid clearance confirmed by PET.

ARIA (Amyloid-Related Imaging Abnormalities) management: All patients on anti-amyloid MAbs require surveillance brain MRI (pre-treatment, after doses 2, 4, 7, and then 6-monthly). ARIA is subclinical in 75% of cases; symptomatic ARIA requires temporary or permanent dose suspension depending on severity. Guidelines from the GAP-NET consortium define mild, moderate, and severe ARIA protocols.

Current AD treatments provide benefits across multiple domains, though the magnitude of effect differs substantially by therapy class:

• Symptomatic benefit from ChEIs: Donepezil and rivastigmine demonstrate statistically significant but modest benefits on cognitive scales (ADAS-Cog: approximately 2.5-point improvement versus placebo at 6 months), functional scales (ADCS-ADL), and neuropsychiatric inventory scores. Most importantly, ChEIs slow functional decline rather than halting disease progression, extending independence in activities of daily living and delaying institutionalisation.
• Disease-slowing with anti-amyloid MAbs: Lecanemab and donanemab represent the first treatments that directly target the underlying biology of Alzheimer's disease and produce a meaningful, statistically significant slowing of clinical progression (27–35% relative reduction in decline rate versus placebo). This translates to an estimated 4–7 months' delay in reaching the next clinical stage over 18 months of treatment — a modest but clinically meaningful benefit in the context of an irreversible neurodegenerative disease.
• Amyloid clearance: Both anti-amyloid antibodies produce near-complete clearance of brain amyloid burden on PET imaging, confirming target engagement. Whether amyloid clearance beyond clinical trial duration translates to sustained clinical benefit is being evaluated in long-term extension studies.
• Caregiver benefit: ChEIs and anti-amyloid therapies in early AD are associated with reduced caregiver burden, delayed nursing home placement, and reduced total societal cost of care in health economic models, offsetting a proportion of their treatment costs.
• Prevention benefit (modifiable risks): Implementing the Lancet Commission 2024 framework — treating midlife hypertension, hearing loss, depression, physical inactivity, smoking, obesity, diabetes, and social isolation — is estimated to prevent or delay up to 45% of dementia cases. These interventions offer population-level benefit even in the absence of a cure.
• Quality of life: Non-pharmacological interventions (cognitive stimulation therapy, reminiscence therapy, music therapy) produce significant improvements in quality of life for people with dementia independent of pharmacological effects.

Each treatment category carries distinct risk profiles that require careful monitoring and patient-carer counselling:

Cholinesterase inhibitors:

• Gastrointestinal: nausea, vomiting, diarrhoea, and anorexia are the most common adverse effects, particularly during dose escalation. Transdermal rivastigmine patch has significantly lower GI side effect rates than oral formulations.
• Cardiovascular: bradycardia and syncope via vagotonic effect; caution in patients with sick sinus syndrome, significant heart block, or QTc prolongation. Baseline ECG recommended before initiation.
• Muscle cramps and nightmares (donepezil, particularly at 10 mg dose): if bothersome, switch from evening to morning dosing or reduce dose temporarily.

Memantine:

• Generally well tolerated. Most common side effects: dizziness, headache, constipation, and hypertension. CNS effects (confusion, somnolence) occur rarely at standard doses.
• Dose reduction required in severe renal impairment (eGFR below 30 mL/min).

Anti-amyloid monoclonal antibodies — ARIA (critical risk):

• ARIA-E (amyloid-related imaging abnormality — oedema/effusion): Detected in 21.5% (lecanemab) and 24.0% (donanemab) of treated patients on MRI. Usually asymptomatic (75% of cases); when symptomatic: headache, confusion, visual changes, unsteadiness, and — rarely — seizures.
• ARIA-H (microhemorrhage and superficial siderosis): 17% (lecanemab) and 31.4% (donanemab). Most microhemorrhages are subclinical and self-limiting.
• APOE4 homozygotes face the highest ARIA risk: ARIA-E in approximately 33% on lecanemab; requires mandatory APOE genotyping before prescribing with enhanced MRI surveillance frequency.
• Fatal ARIA cases: Rare (3 deaths potentially related to ARIA on lecanemab during trials, some in patients on anticoagulants). Concurrent anticoagulant therapy is an important relative or absolute contraindication depending on prescribing protocol.
• Infusion-related reactions (lecanemab): Occur in 26.4% of patients with first infusion, mostly mild (chills, flushing, nausea); pre-medication with antihistamine and paracetamol is standard.

BPSD pharmacological management risks: Atypical antipsychotics (risperidone, quetiapine) carry black-box warnings for increased risk of mortality in elderly patients with dementia; use only at lowest effective dose for shortest necessary period for severe agitation or psychosis.

Effective follow-up for Alzheimer's disease integrates pharmacological monitoring, functional assessment, caregiver support, and proactive safety planning across the disease trajectory.

ChEI and memantine monitoring: Review 4–6 weeks after each dose initiation or escalation to assess tolerability and GI side effects. Annual standardised cognitive assessment using MMSE (or MoCA), functional scales, and Neuropsychiatric Inventory (NPI) enables objective tracking of disease progression and treatment response. Annual ECG in patients with cardiac risk factors on ChEIs. Consider stopping ChEI if patient deteriorates to advanced dementia stage with no discernible functional or quality-of-life benefit (this decision should involve patient, carers, and multidisciplinary team).

Anti-amyloid MAb monitoring protocol (lecanemab and donanemab):

• Brain MRI before initiation, after 5th and 7th infusions (dose 2 and 4 at weeks 4 and 12), then every 6 months during treatment.
• Any new neurological symptom during treatment (headache, confusion, visual change, gait unsteadiness) warrants urgent unscheduled MRI to exclude symptomatic ARIA before next infusion.
• Dose suspension for moderate ARIA; permanent discontinuation for severe symptomatic ARIA with large areas of oedema or significant haemorrhage.
• Amyloid PET at 12 months for donanemab (to guide 'stop when clear' protocol); repeat plasma p-tau217 every 6–12 months as a treatment response biomarker is being evaluated in extension studies.

Holistic monitoring across the disease:

• Driving assessment: formal on-road driving assessment should be arranged when a diagnosis of mild AD is confirmed; most jurisdictions require clinicians to notify driving licensing authorities.
• Legal and financial planning: early-stage AD is the optimal time to establish lasting power of attorney, advance care directives, and financial management arrangements while the person retains decision-making capacity.
• Caregiver assessment and support: carers of people with AD face high rates of burnout, depression, and physical illness. Six-monthly carer wellbeing assessments and signposting to dementia support organisations are integral to comprehensive follow-up.
• Immunisation and safety: flu, COVID-19, pneumococcal, and shingles vaccines should be kept up to date; fall-risk assessment and home safety review (stove locks, GPS tracking devices) are recommended from moderate stage onwards.

Alzheimer's disease treatment costs vary dramatically by therapy type, country, healthcare system, and disease stage:

Cholinesterase inhibitors and memantine:

• Generic donepezil, rivastigmine, and memantine are widely available globally at low cost: typically USD $5–$30 per month for generic formulations.
• Brand-name Aricept, Exelon patch, Namenda XR, and Namzaric carry significantly higher costs in the US (USD $200–$600/month without insurance), though most are covered by Medicare Part D and most commercial insurers.
• In India, generic ChEIs are available at INR 200–600/month; in the UK and Australia, they are fully funded under NHS or PBS for eligible patients with confirmed AD dementia.

Anti-amyloid monoclonal antibodies (lecanemab and donanemab):

• Lecanemab (Leqembi) US list price: Approximately USD $26,500 per year (biweekly IV infusions at 10 mg/kg). Medicare covers approximately 80% under Part B (after CMS coverage decision in July 2023 for patients meeting strict eligibility criteria under Coverage with Evidence Development).
• Donanemab (Kisunla) US list price: Approximately USD $32,000 per year (monthly infusions). Similar Medicare/commercial insurance coverage landscape as lecanemab.
• Companion diagnostics: Amyloid PET scan (18F-florbetapir): approximately USD $3,000–$5,000 per scan in the US. CSF analysis: USD $1,000–$2,500. Plasma p-tau217 testing: USD $200–$500 (increasingly insurance-covered as an initial screening tool).
• APOE genotyping: USD $150–$400 for clinical-grade APOE4 genotyping; required before anti-amyloid MAb prescription.
• Infusion centre costs: IV infusion administration adds USD $200–$600 per session beyond drug cost in the US; many centres have established dedicated AD infusion programmes.
• International access: Anti-amyloid MAbs are currently approved in the US (lecanemab: full FDA approval 2023; donanemab: FDA approved 2024), Japan, and a small number of other countries. Regulatory review is ongoing in Europe (EMA) and the UK (MHRA). Compassionate use programmes exist in some regions.

Non-pharmacological interventions: Cognitive stimulation therapy (CST), delivered in group settings by trained facilitators, costs USD $10–$30 per session and is cost-effective relative to pharmacological therapies. Occupational therapy home assessment and adaptation: USD $500–$2,000. Carer respite services and adult day programmes vary widely by country and eligibility criteria.

A growing body of evidence supports non-pharmacological and lifestyle-based strategies that complement — and in some cases may delay the onset of — Alzheimer's disease:

• MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay): A hybrid of Mediterranean and DASH diets emphasising leafy green vegetables, berries (particularly blueberries), nuts, whole grains, fish, poultry, olive oil, and legumes while minimising red meat, butter, cheese, pastry, and fried food. Observational studies show adherence to the MIND diet is associated with slower cognitive decline, equivalent to a cognitively younger age of 7.5 years in the MIND cohort. RCT data (MIND trial, 2023) showed significant cognitive benefit in older adults over 3 years.
• Aerobic physical exercise: Consistent evidence from RCTs supports 150 minutes per week of moderate-intensity aerobic exercise (brisk walking, swimming, cycling) as the single most potent non-pharmacological intervention to slow cognitive decline in MCI and early AD. Exercise increases BDNF (brain-derived neurotrophic factor), hippocampal volume, and cerebral blood flow, and reduces systemic inflammation.
• Cognitive stimulation therapy (CST): A structured 14-session group intervention focused on cognitive activities and social interaction. Cochrane meta-analysis demonstrates significant benefits for cognition and quality of life compared to usual care; NICE recommends CST for all people with mild-to-moderate dementia.
• Hearing aids and hearing loss treatment: The Lancet Commission 2024 identifies hearing loss as the single largest modifiable dementia risk factor in midlife. Treating hearing loss with appropriately fitted hearing aids reduces the pace of cognitive decline in older adults (ACHIEVE trial RCT, 2023) — a potentially transformative, accessible, and affordable public health intervention.
• Vascular risk management: Treating hypertension in midlife (particularly systolic BP above 130 mmHg), managing type 2 diabetes, reducing LDL cholesterol (newly added by Lancet 2024), and smoking cessation collectively address major cerebrovascular contributors to AD pathology and may substantially reduce lifetime dementia risk.
• Social engagement and cognitive reserve: Regular social interaction, lifelong learning, bilingualism, occupational complexity, and high educational attainment build cognitive reserve that delays the clinical expression of underlying AD pathology even when neuropathological burden is identical to cognitively impaired individuals.
• Clinical trials: For patients with early AD confirmed on biomarkers, participation in clinical trials of emerging therapies (tau-directed antibodies, BACE inhibitors, synaptic vesicle protein 2A ligands, GLP-1 receptor agonists) offers access to cutting-edge therapies while contributing to the evidence base. ClinicalTrials.gov lists currently enrolling AD intervention trials.